JP7698317B2 - がん治療のためのセプチン阻害剤 - Google Patents

がん治療のためのセプチン阻害剤 Download PDF

Info

Publication number
JP7698317B2
JP7698317B2 JP2022507705A JP2022507705A JP7698317B2 JP 7698317 B2 JP7698317 B2 JP 7698317B2 JP 2022507705 A JP2022507705 A JP 2022507705A JP 2022507705 A JP2022507705 A JP 2022507705A JP 7698317 B2 JP7698317 B2 JP 7698317B2
Authority
JP
Japan
Prior art keywords
cancer
septin
cell
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022507705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545181A5 (https=
JP2022545181A (ja
Inventor
ケイ． シン，ラケシュ
ケイ． キム，キュ
ターナー，レイチェル
ジー． ムーア，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of JP2022545181A publication Critical patent/JP2022545181A/ja
Publication of JP2022545181A5 publication Critical patent/JP2022545181A5/ja
Application granted granted Critical
Publication of JP7698317B2 publication Critical patent/JP7698317B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
JP2022507705A 2019-08-30 2020-08-31 がん治療のためのセプチン阻害剤 Active JP7698317B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962894424P 2019-08-30 2019-08-30
US62/894,424 2019-08-30
PCT/US2020/048712 WO2021042022A1 (en) 2019-08-30 2020-08-31 Septin inhibitors for treatment of cancers

Publications (3)

Publication Number Publication Date
JP2022545181A JP2022545181A (ja) 2022-10-26
JP2022545181A5 JP2022545181A5 (https=) 2023-08-21
JP7698317B2 true JP7698317B2 (ja) 2025-06-25

Family

ID=72517327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507705A Active JP7698317B2 (ja) 2019-08-30 2020-08-31 がん治療のためのセプチン阻害剤

Country Status (4)

Country Link
US (1) US12433876B2 (https=)
EP (1) EP4021894A1 (https=)
JP (1) JP7698317B2 (https=)
WO (1) WO2021042022A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250268980A1 (en) * 2022-04-22 2025-08-28 The Board Of Regents Of The University Of Texas System An anticancer therapy targeting ras and other oncogenic signals by inhibition of dynamic blebbing and/or septins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538152A (ja) 2002-09-05 2005-12-15 ニューロサーチ、アクティーゼルスカブ ジアリール誘導体及びこれをクロライドチャネル遮断剤として使用する方法
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
JP2017526711A (ja) 2014-09-10 2017-09-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物
CN109705031A (zh) 2018-11-29 2019-05-03 浙江泰达作物科技有限公司 一种吡啶苯基脲类化合物及其在化妆品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426031A (en) * 1967-01-19 1969-02-04 Dow Chemical Co 3,5,6 - trichloro - 4 - (3 - (alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro - 3,5 - xylyl)ureido) picolinic acid and the corresponding amide derivative
GB2068365B (en) 1980-02-05 1983-12-14 Dow Chemical Co Fungicidal pyridyl arylureas
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0840623B1 (en) 1995-07-21 2007-07-18 Brown University Research Foundation Compositions for gene therapy comprising nucleic acid loaded polymeric microparticles
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
WO2020126968A2 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538152A (ja) 2002-09-05 2005-12-15 ニューロサーチ、アクティーゼルスカブ ジアリール誘導体及びこれをクロライドチャネル遮断剤として使用する方法
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
JP2017526711A (ja) 2014-09-10 2017-09-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物
CN109705031A (zh) 2018-11-29 2019-05-03 浙江泰达作物科技有限公司 一种吡啶苯基脲类化合物及其在化妆品中的应用

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Abad, Antonio; et al.，X-ray Structure of Fluorinated N-(2-Chloropyridin-4-yl)-N'-phenylureas. Role of F Substitution in the Crystal Packing.，Crystal Growth & Design，2006年，6(1)，p.46-57
ATSUYA TAKAMI; ET AL.，DESIGN AND SYNTHESIS OF RHO KINASE INHIBITORS(I)，BIOORGANIC & MEDICINAL CHEMISTRY，NL，ELSEVIER，2004年05月，VOL:12, NR:9，PAGE(S):2115-2137，http://dx.doi.org/10.1016/j.bmc.2004.02.025
Bhasker, G. Vijaya; et al.，Synthesis and antimicrobial activity of novel 1-[3-(1,8-naphthyridin-2-yl)phenyl]-3-arylurea derivatives.，Asian Journal of Chemistry，2018年，30(4)，p.771-774
Henrie, Robert N., II; et al.，Activity optimization of pyridinyl N-oxide urea cytokinin mimics.，Journal of Agricultural and Food Chemistry，1988年，36(3)，p.626-33
Ichihara, Osamu; et al.，Development of self-indicating resin.1，Combinatorial Chemistry & High Throughput Screening，2007年，10(4)，p.261-267
QICONG HU; ET AL.，FORCHLORFENURON ALTERS MAMMALIAN SEPTIN ASSEMBLY, ORGANIZATION, AND DYNAMICS，JOURNAL OF BIOLOGICAL CHEMISTRY，米国，2008年10月24日，VOL:283, NR:43，PAGE(S):29563-29571，http://dx.doi.org/10.1074/jbc.M804962200
SANNA LEHTONEN; ET AL.，SEPTINS IN KIDNEY: A TERRITORY LITTLE EXPLORED，CYTOSKELETON，2018年07月13日，VOL:76，PAGE(S):154-162，https://doi.org/10.1002/cm.21477
SOSHIRO TAKAHASHI; ET AL.，CYTOKININ ACTIVITY OF N-PHENYL-N′-(4-PYRIDYL)UREA DERIVATIVES，PHYTOCHEMISTRY，NL，1978年，VOL:17, NR:8，PAGE(S):1201-1207，http://dx.doi.org/10.1016/S0031-9422(00)94556-4
Suarez-Pantaleon, Celia; et al.，Forchlorfenuron-mimicking haptens: from immunogen design to antibody characterization by hierarchical clustering analysis.，Organic & Biomolecular Chemistry，2011年，9(13)，p.4863-4872

Also Published As

Publication number Publication date
US12433876B2 (en) 2025-10-07
JP2022545181A (ja) 2022-10-26
US20220280491A1 (en) 2022-09-08
EP4021894A1 (en) 2022-07-06
WO2021042022A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
US12152085B2 (en) Compositions and methods to regulate Renalase in the treatment of cancer
US9694015B2 (en) Methods for the treatment of locally advanced breast cancer
CA2646222C (en) Nitrofuran compounds for the treatment of cancer and angiogenesis
MX2013012564A (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2012010367A (es) Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
JP2018524347A (ja) 血液がん及び固形腫瘍の治療のための併用療法
KR20230059792A (ko) 암 치료를 위한 조합
JP7698317B2 (ja) がん治療のためのセプチン阻害剤
US20210355235A1 (en) Compositions and Methods For Treating Cancer with Anti-Renalase antibodies and Anti-PD1 antibodies
US20250114331A1 (en) Concurrent targeting of oncogenic pathways to enhance chemotherapy and immunotherapy
CA2953807C (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

R150 Certificate of patent or registration of utility model

Ref document number: 7698317

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150